You are here: Industry Insights > NIH

News List

NIH scientists identify two drug candidates for AMD treatment Pharmaceutical-Technology
December 17, 2021
Researchers at the US National Institutes of Health (NIH) unit National Eye Institute (NEI) have identified two potential drug candidates for age-related macular degeneration (AMD) treatment.
New Rapid Molecular COVID-19 Test from Anavasi Diagnostics Awarded $14.9 Million by NIH to Accelerate Test Availability AmericanPharmaceuticalReview
November 12, 2021
Anavasi Diagnostics, a medical technology company focused on the development of novel molecular diagnostic testing using a proprietary patent-pending reverse transcriptase methodology...
NIH study says repurposed cancer therapies beneficial for Alzheimer’s Pharmaceutical-Technology
November 12, 2021
Scientists from the US National Institutes of Health (NIH) unit National Institute on Aging (NIA) have found that present and developing therapies for cancer could potentially...
FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases WorldPharmaNews
October 29, 2021
The U.S. Food and Drug Administration, the National Institutes of Health, 10 pharmaceutical companies and five non-profit organizations have partnered to accelerate development of gene therapies...
Privo Technologies Awarded $3M NIDCR NIH Commercialization Readiness Pilot Grant firstwordpharma
August 24, 2021
Privo Technologies, Inc. ("Privo") announced today that the National Institute of Dental and Craniofacial Research of NIH has awarded Privo approximately $3 million over three years in a Commercialization Readiness Pilot (CRP) grant as part of the SRIR.
NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms firstwordpharma
August 19, 2021
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19.
NIH hamster study evaluates airborne and fomite transmission of SARS-CoV-2 firstwordpharma
August 18, 2021
National Institutes of Health scientists studying SARS-CoV-2, the virus that causes COVID-19, have defined in Syrian hamsters how different routes of virus exposure are linked to disease severity.
Monoclonal antibody prevents malaria in small NIH trial europeanpharmaceuticalreview
August 13, 2021
One dose of a monoclonal antibody developed at the US National Institutes of Health (NIH) prevented malaria for up to nine months.
NIH launches study of third COVID-19 vaccine dose in kidney transplant recipients expresspharma
August 12, 2021
A pilot study has begun to assess the antibody response to a third dose of an authorised COVID-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech COVID-19 vaccine.
NIH trial closes enrolment for Brii Biosciences’ Covid-19 antibodies pharmaceutical-technology
August 06, 2021
Brii Biosciences has reported that the National Institutes of Health (NIH)’s ACTIV-2 clinical trial in the US completed enrolment for the Phase III part assessing its combination treatment, BRII-196 plus BRII-198, for Covid-19.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page